Research programme: diabetes therapy - OrganonAlternative Names: Org 211559
Latest Information Update: 16 Nov 2009
At a glance
- Originator Organon
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 25 Jan 2007 Preclinical trials in Diabetes mellitus in USA (unspecified route)